Skip to main
ERAS
ERAS logo

Erasca Inc (ERAS) Stock Forecast & Price Target

Erasca Inc (ERAS) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 45%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Erasca Inc. demonstrates a strong positive outlook due to its promising clinical pipeline, which includes innovative treatments that target the RAS/MAPK pathway, specifically Naporafenib for NRASm melanoma and various other solid tumors. The company reports encouraging median overall survival (mOS) results of 13.0 to 14.1 months, significantly surpassing traditional therapies, which positions its combination therapies favorably in the market. Furthermore, the anticipated upcoming catalysts, including pivotal trial data filings for its lead compounds ERAS-0015 and ERAS-4001 expected in 2025 and 2026 respectively, add to its growth potential despite shares currently trading at cash value.

Bears say

Erasca Inc. has demonstrated limited efficacy in its clinical trials, particularly evident in the SEACRAFT-1 study, which reported a mere 23% response rate among non-melanoma tumor types, indicating challenges in addressing the complex feedback mechanisms in MAPK-mutated tissues. The company experienced a significant increase in net loss, reporting $63.2 million, or ($0.29 per share), for the second quarter of 2024, compared to a net loss of $31.7 million, or ($0.21 per share), in the same period the previous year. These financial struggles, coupled with the clinical effectiveness issues faced in their development pipeline, contribute to a negative outlook for Erasca's stock.

Erasca Inc (ERAS) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 45% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Erasca Inc (ERAS) Forecast

Analysts have given Erasca Inc (ERAS) a Buy based on their latest research and market trends.

According to 11 analysts, Erasca Inc (ERAS) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Erasca Inc (ERAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.